N/A
Manufactured by Haleon US Holdings LLC
1,242 FDA adverse event reports analyzed
Last updated: 2026-04-15
DEXTROMETHORPHAN POLISTIREX is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Haleon US Holdings LLC. The most commonly reported adverse reactions for DEXTROMETHORPHAN POLISTIREX include DRUG INEFFECTIVE, DIARRHOEA, DIZZINESS, NAUSEA, DRUG EFFECT INCOMPLETE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for DEXTROMETHORPHAN POLISTIREX.
Out of 748 classified reports for DEXTROMETHORPHAN POLISTIREX:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 1,242 FDA FAERS reports that mention DEXTROMETHORPHAN POLISTIREX. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, DIARRHOEA, DIZZINESS, NAUSEA, DRUG EFFECT INCOMPLETE, HYPERSENSITIVITY. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Haleon US Holdings LLC in connection with DEXTROMETHORPHAN POLISTIREX. Always verify the specific product and NDC with your pharmacist.